DEA Officially Bans HHC, Hemp's Sketchy Cousin, Nationwide
Published Date: 5/4/2026
Rule
Summary
The DEA is giving hexahydrocannabinol (HHC) its own official spot on the list of Schedule I drugs, making it clear that HHC is controlled separately from other similar substances. This change starts May 4, 2026, and affects anyone making, selling, or using HHC, which stays illegal under federal law. No new fees or costs are introduced, but the update helps law enforcement and businesses know exactly where HHC stands.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
HHC Listed Separately in Schedule I
The DEA added hexahydrocannabinol (HHC) as its own specific Schedule I listing with DEA drug code 7220, effective May 4, 2026. HHC remains a Schedule I controlled substance (it was previously controlled under the tetrahydrocannabinols drug code 7370), so making, selling, or using HHC stays illegal under federal law.
DEA Can Set HHC Production Quotas
The rule lets DEA establish an aggregate production quota and grant individual manufacturing and procurement quotas specifically for HHC (hexahydrocannabinol). DEA-registered manufacturers of HHC, who previously received quotas under the tetrahydrocannabinols drug code, will receive quotas tied to the new HHC drug code.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-13364 — Schedules of Controlled Substances: Temporary Placement of 5,6- Dichloro Brorphine, 5,6-Dichloro Desmethylchlorphine, N-Propionitrile Chlorphine, and Spirochlorphine in Schedule I of the Controlled Substances Act
Starting July 1, 2026, the DEA is temporarily putting four new substances—5,6-dichloro brorphine, 5,6-dichloro desmethylchlorphine, N-propionitrile chlorphine, and spirochlorphine—into Schedule I, the strictest drug category. This means anyone making, selling, or using these chemicals will face tough legal rules and penalties. The move helps keep these potentially dangerous drugs off the streets while the DEA studies them further.
2026-13145 — Importer of Controlled Substances Application: Almac Clinical Services Incorp. (ACSI)
Almac Clinical Services Incorp. (ACSI) wants to become an official importer of certain controlled substances, including psilocybin and oxycodone. This affects drug manufacturers and others in the industry who can comment or request a hearing by July 30, 2026. No direct costs are mentioned, but the decision could impact how these substances enter the U.S. market.
2026-13144 — Importer of Controlled Substances Application: Catalent Pharma Solutions, LLC
Catalent Pharma Solutions wants to become an official importer of some powerful controlled substances like LSD and psilocybin. People who make or use these drugs can share their thoughts or ask for a hearing by July 30, 2026. This move could impact companies involved in these substances and the government’s control over them.
2026-12653 — Schedules of Controlled Substances: Placement of Bromazolam in Schedule I; Correction
The DEA fixed a typo in the official chemical name of bromazolam, a drug they put in the strictest Schedule I category starting March 16, 2026. This correction makes the rules clear for everyone involved, especially law enforcement and drug handlers. No new fees or deadlines, just a clean-up to keep things accurate and official.
Previous / Next Documents
Previous: 2026-08580 — Removal of Standard of Identity for Canned “Tripe With Milk”
Starting June 3, 2026, canned “Tripe with Milk” won’t have a strict recipe to follow anymore. This change lets producers get creative while still making sure labels tell the truth. It’s good news for businesses who want more freedom without confusing customers or costing extra.
Next: 2026-08599 — Fisheries of the Northeastern United States; Summer Flounder Fishery; Quota Transfer From Virginia to New Jersey
Virginia is sharing some of its 2026 summer flounder fishing quota with New Jersey to help both states meet their fishing goals. This change kicks in on May 1, 2026, and lasts through the end of the year. Fishermen in both states should get ready for the updated limits, which keep the fishery fair and balanced without affecting overall catch limits.